Micronized Device for the Delivery of Biologically Active Molecules and Methods of Use Thereof
AssigneeNeurotech USA, Inc.
InventorsKonrad Kauper, Weng Tao, Paul Stabila
Life of this patent
Estimating the term…
Abstract
The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorders in patients suffering there from.
Claims6
-26. (canceled)
A method for delivering a biologically active molecule to the eye, the method comprising implanting at least one micronized device for delivery of a therapeutic dose of a biologically active molecule to the eye comprising a capsule into the eye or surrounding the eye and allowing said biologically active molecule to diffuse from the device into the vitreous, the aqueous humor, or the periocular space of the eye, wherein the capsule comprises:
- a) a core comprising between about 5×102 and 90×203 living cells that produce a biologically active molecule, wherein the core has a volume of less than 0.5 μl, and
- b) a biocompatible jacket surrounding said core, the jacket having a molecular weight cutoff permitting diffusion of the biologically active molecule into the eye,
- wherein the device is configured as a cylinder with an outer diameter of between 200 and 350 μm and a length of between 0.5 and 6 mm, wherein the therapeutic dosage of the biologically active molecule that diffuses into the eye is between 0.1 pg and 1000 ng per eye per patient per day for a period greater than three months.
A method for treating ophthalmic disorders in a patient suffering there from, comprising implanting a micronized device for delivery of a therapeutic dose of a biologically active molecule to the eye comprising a capsule into an eye of the patient, wherein the capsule comprises:
- a) a core comprising between about 5×102 and 90×203 living cells that produce a biologically active molecule, wherein the core has a volume of less than 0.5 μl, and
- b) a biocompatible jacket surrounding said core, the jacket having a molecular weight cutoff permitting diffusion of the biologically active molecule into the eye,
- wherein the device is configured as a cylinder with an outer diameter of between 200 and 350 μm and a length of between 0.5 and 6 mm, wherein the therapeutic dosage of the biologically active molecule that diffuses into the eye is between 0.1 pg and 1000 ng per eye per patient per day for a period greater than three months.
Dependencies are inferred from the claim text.